Navigation

Cardura

Cardura (Doxazosin Mesylate) side effects drug center

 

PROFESSIONAL

CONSUMER

SIDE EFFECTS

 

Cardura Side Effects Center

What Is Cardura?

Cardura (doxazosin) is an alpha-1 adrenergic blocker prescribed for treating high blood pressure, and symptoms associated with benign prostatic hyperplasia (BPH, a noncancerous enlargement of the prostate gland). Cardura is available as a generic drug.

What Are Side Effects of Cardura?

Common side effects of Cardura include:

Tell your doctor if you experience serious side effects of Cardura including:

Dosage for Cardura

Cardura dosage ranges from 1-16 mg daily depending on the indication.

What Drugs, Substances, or Supplements Interact with Cardura?

Cardura may interact with sildenafil, tadalafil, vardenafil, or other blood pressure medications, including diuretics (water pills). Tell your doctor all medications and supplements you use.

Cardura During Pregnancy and Breastfeeding

Cardura has not been sufficiently studied in pregnant women and nursing mothers. Consult your doctor before breastfeeding.

Additional Information

Our Cardura Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

 

Cardura Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • a light-headed feeling, like you might pass out;
  • severe ongoing stomach pain or bloating;
  • new or worsening chest pain;
  • trouble breathing; or
  • a penis erection that is painful or lasts 4 hours or longer.

Common side effects may include:

  • low blood pressure, dizziness;
  • drowsiness;
  • headache; or
  • feeling weak or tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Cardura (Doxazosin Mesylate)

 

Cardura Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Benign Prostatic Hyperplasia (BPH)

The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients. The incidence rates presented below (Table 2) are based on combined data from seven placebo-controlled trials involving once-daily administration of CARDURA in doses of 1 to 16 mg in hypertensives and 0.5 to 8 mg in normotensives. Adverse reactions occurring more than 1% more frequently in BPH patients treated with CARDURA vs placebo are summarized in Table 1.

Table 1: Adverse Reactions Occurring more than 1% More Frequently in BPH Patients Treated with Cardura Versus Placebo

BODY SYSTEM Cardura
N=665		 Placebo
N=300
NERVOUS SYSTEM DISORDERS
  Dizziness† 15.6% 9.0%
  Somnolence 3.0% 1.0%
CARDIAC DISORDERS
  Hypotension 1.7% 0%
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
  Dyspnoea 2.6% 0.3%
GASTROINTESTINAL DISORDERS
  Dry Mouth 1.4% 0.3%
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
  Fatigue 8.0% 1.7%
  Oedema 2.7% 0.7%
†Includes vertigo

Other adverse reactions occurring less than 1% more frequently in BPH patients treated with CARDURA vs placebo but plausibly related to CARDURA include: palpitations.

Hypertension

CARDURA has been administered to approximately 4000 hypertensive patients in clinical trials, of whom 1679 were included in the hypertension clinical development program. In placebo-controlled studies, adverse events occurred in 49% and 40% of patients in the doxazosin and placebo groups, respectively, and led to discontinuation in 2% of patients in each group.

Adverse reactions occurring more than 1% more frequently in hypertensive patients treated with CARDURA vs placebo are summarized in Table 1. . Postural effects and edema appeared to be dose-related. The prevalence rates presented below are based on combined data from placebo-controlled studies involving once-daily administration of doxazosin at doses ranging from 1 to 16 mg.

Table 2: Adverse Reactions Occurring more than 1% More Frequently in Hypertensive Patients Treated with Cardura versus Placebo

BODY SYSTEM Cardura
N=339		 Placebo
N=336
NERVOUS SYSTEM DISORDERS
  Dizziness 19% 9%
  Somnolence 5% 1%
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
  Rhinitis 3% 1%
RENAL AND URINARY DISORDERS
  Polyuria 2% 0%
REPRODUCTIVE SYSTEM AND BREAST DISORDERS GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
  Fatigue / Malaise 12% 6%

Other adverse reactions occurring less than 1% more frequently in hypertensive patients treated with CARDURA vs placebo but plausibly related to CARDURA use include vertigo, hypotension, hot flushes, epistaxis and oedema.

CARDURA has been associated with decreases in white blood cell counts

Laboratory Changes Observed In Clinical Studies

Leukopenia/Neutropenia: Decreases in mean white blood cell (WBC) and mean neutrophil count were observed in controlled clinical trials of hypertensive patients receiving CARDURA. In cases where follow-up was available, WBC and neutrophil counts returned to normal after discontinuation of CARDURA. No patients became symptomatic as a result of the low WBC or neutrophil counts.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of CARDURA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In post-marketing experience, the following additional adverse reactions have been reported:

Blood and Lymphatic System Disorders: leukopenia, thrombocytopenia;

Immune System Disorders: allergic reaction;

Nervous System Disorders: hypoesthesia;

Eye Disorders: Intraoperative Floppy Iris Syndrome [see WARNINGS AND PRECAUTIONS];

Cardiac Disorders: bradycardia;

Respiratory, Thoracic and Mediastinal Disorders: bronchospasm aggravated;

Gastrointestinal Disorders: vomiting;

Hepatobiliary Disorders: cholestasis, hepatitis cholestatic;

Skin and Subcutaneous Tissue Disorders: urticaria;

Musculoskeletal and Connective Tissue Disorders: muscle cramps, muscle weakness;

Renal and Urinary Disorders: hematuria, micturition disorder, micturition frequency, nocturia;

Reproductive System and Breast Disorders: gynecomastia, priapism.

Read the entire FDA prescribing information for Cardura (Doxazosin Mesylate)

&Copy; Cardura Patient Information is supplied by Cerner Multum, Inc. and Cardura Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.